Cargando…

Evaluation of the Effectiveness of the Risk Minimization Measures of Sodium Oxybate in the European Union

BACKGROUND: Sodium oxybate (Xyrem(®)), approved by the European Medicines Agency (EMA) for narcolepsy with cataplexy, is only available through risk mitigation programs due to potential adverse effects including respiratory and central nervous system depression, neuropsychiatric events, and misuse....

Descripción completa

Detalles Bibliográficos
Autores principales:	Iranzo, Alex, Serralheiro, Pedro, Schuller, Jan-Christof, Schlit, Anne-Françoise, Bentz, Jürgen W. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581670/ https://www.ncbi.nlm.nih.gov/pubmed/32989679 http://dx.doi.org/10.1007/s40801-020-00212-9

Ejemplares similares

Sleep, Narcolepsy, and Sodium Oxybate
por: Mamelak, Mortimer
Publicado: (2022)

Sodium Oxybate: a Substitute for Alcohol?
por: Gual, A., et al.
Publicado: (2022)

Psychosis in Patients with Narcolepsy as an Adverse Effect of Sodium Oxybate
por: Sarkanen, Tomi, et al.
Publicado: (2014)

Long-Term Treatment of Narcolepsy and Idiopathic Hypersomnia with Low-Sodium Oxybate
por: Schneider, Logan D, et al.
Publicado: (2023)

Sodium oxybate—a new horizon for symptomatic treatment of RBD?
por: Stefani, Ambra, et al.
Publicado: (2023)

Off-label Sodium Oxybate in Childhood Narcolepsy: A Comprehensive Report
por: Miskoff, Jeffrey A, et al.
Publicado: (2018)

Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1
por: Schinkelshoek, Mink S., et al.
Publicado: (2018)

Effectiveness of Additional Risk Minimization Measures for Atezolizumab in the European Union
por: Patel, Hina, et al.
Publicado: (2021)

Long-term Effect of Sodium Oxybate (Xyrem®) in Spasmodic Dysphonia with Vocal Tremor
por: Simonyan, Kristina, et al.
Publicado: (2013)

A Case of Off-label Sodium Oxybate in an 11-Year-Old with Narcolepsy
por: Miskoff, Jeffrey A, et al.
Publicado: (2019)

Sodium oxybate in treatment-resistant rapid-eye-movement sleep behavior disorder
por: During, Emmanuel H, et al.
Publicado: (2023)

Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy
por: Bogan, Richard K, et al.
Publicado: (2020)

Corrigendum to: Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy
por: Bogan, Richard K, et al.
Publicado: (2021)

Corrigendum to: Efficacy and Safety of Calcium, Magnesium, Potassium, and Sodium Oxybates (Lower-Sodium Oxybate [LXB]; JZP-258) in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adults With Narcolepsy With Cataplexy
por: Bogan, Richard K, et al.
Publicado: (2021)

A Brief Up-Date of the Use of Sodium Oxybate for the Treatment of Alcohol Use Disorder
por: Caputo, Fabio, et al.
Publicado: (2016)

Increasing Evidence for the Use of Sodium Oxybate in Multi-Drug-Resistant Lance–Adams Syndrome
por: Riboldi, Giulietta M., et al.
Publicado: (2019)

Sodium Oxybate: A Cause of Extreme Involuntary Weight Loss in a Young Lady
por: Noujaim, Michael G., et al.
Publicado: (2019)

REM Sleep Behavior Disorder in Children With Type 1 Narcolepsy Treated With Sodium Oxybate
por: Antelmi, Elena, et al.
Publicado: (2021)

Preferences for Attributes of Sodium Oxybate Treatment: A Discrete Choice Experiment in Patients with Narcolepsy
por: Dubow, Jordan, et al.
Publicado: (2022)

Correction to: Sodium oxybate in treatment-resistant rapid-eye-movement sleep behavior disorder
Publicado: (2023)

O024 Sodium oxybate for refractory narcolepsy and idiopathic hypersomnia: clinical and employment outcomes
por: Hernest, A, et al.
Publicado: (2023)

Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing
por: Feldman, Neil T.
Publicado: (2009)

Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial
por: Spaeth, Michael, et al.
Publicado: (2012)

A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome
por: George, Charles F. P., et al.
Publicado: (2010)

Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice
por: Drakatos, Panagis, et al.
Publicado: (2017)

Resolution of Sleepwalking Behavior after Initiation of Sodium Oxybate in a Patient with Narcolepsy Type 2
por: Hesselbacher, Sean, et al.
Publicado: (2018)

Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav(®)) in Sleep Disorders: A Profile of Its Use
por: Heo, Young-A
Publicado: (2022)

The Xyrem(®) (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: Results From 2016 to 2017
por: Strunc, Michael J., et al.
Publicado: (2021)

Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re‐evaluation of an established drug
por: Schlit, Anne‐Françoise, et al.
Publicado: (2017)

Population and Noncompartmental Pharmacokinetics of Sodium Oxybate Support Weight‐Based Dosing in Children and Adolescents With Narcolepsy With Cataplexy
por: Chen, Cuiping, et al.
Publicado: (2020)

Correction to: Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav(®)) in Sleep Disorders: A Profile of Its Use
por: Heo, Young-A
Publicado: (2022)

Sodium Oxybate for Alcohol Dependence: A Network Meta-Regression Analysis Considering Population Severity at Baseline and Treatment Duration
por: Guiraud, Julien, et al.
Publicado: (2023)

Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial
por: Guiraud, Julien, et al.
Publicado: (2022)

Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
por: Dauvilliers, Yves, et al.
Publicado: (2022)

Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia
por: Spaeth, Michael, et al.
Publicado: (2013)

A novel therapeutic agent, sodium oxybate, improves dystonic symptoms via reduced network-wide activity
por: Simonyan, Kristina, et al.
Publicado: (2018)

Pharmacokinetics, bioavailability, and bioequivalence of lower‐sodium oxybate in healthy participants in two open‐label, randomized, crossover studies
por: Chen, Cuiping, et al.
Publicado: (2021)

Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications
por: Dauvilliers, Yves, et al.
Publicado: (2022)

Measuring health expectancy in the European Union
por: Santos, JV, et al.
Publicado: (2022)

Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment
por: Morse, Anne Marie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_05o471l0169c3rmv88mcrku1be